<- Go Home
Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Market Cap
CAD 31.1M
Volume
4.3K
Cash and Equivalents
N/A
EBITDA
-CAD 5.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
38.00%
52 Week High
CAD 2.99
52 Week Low
CAD 0.85
Dividend
N/A
Price / Book Value
2.69
Price / Earnings
-4.14
Price / Tangible Book Value
127.98
Enterprise Value
CAD 30.0M
Enterprise Value / EBITDA
-5.72
Operating Income
N/A
Return on Equity
49.88%
Return on Assets
-17.78
Cash and Short Term Investments
N/A
Debt
N/A
Equity
N/A
Revenue
N/A
Unlevered FCF
CAD 276.3K
Sector
Biotechnology
Category
N/A